Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Metagenomic Plasmabased Test For Agnostic Pathogen Detection

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07110636Not ApplicableRecruiting

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

NCT00300677Phase 4CompletedPrimary

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

Showing all 2 trials

Research Network

Common Treatments

  • Metagenomic Plasmabased Test For Agnostic Pathogen Detection1
  • Voriconazole1

Active Sponsors

  • Karius, Inc.1
  • McLean Hospital. Belmont, MA.1
  • Pfizer1

Top Investigators

Related Conditions

  • Infection1
  • Infections Bacterial1
  • Parasitic Disease1
  • Infection Viral1

Activity Timeline